Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus MAGNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus MAGNACORT.
KENALOG IN ORABASE vs MAGNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Category C
Category C
Corticosteroid
Corticosteroid